Małgorzata Pasztelan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Małgorzata Pasztelan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Marczak
Student Research Group at the Department of Clinical Oncology and Chemotherapy, Medical University of Lublin
5 shared publications - Aleksandra Muca
University Clinical Hospital No. 1 in Lublin, ul. Stanisława Staszica 16, 20-081 Lublin, Poland
5 shared publications - Jarosław Pulikowski
4th Clinical University Hospital in Lublin, ul. Kazimierza Jaczewskiego 8, 20-954 Lublin, Poland
5 shared publications - Joanna Baran
St. Vincent de Paul Hospital, ul. Wójta Radtkego 1, 81-348 Gdynia, Poland
5 shared publications - Julia Krawczuk Vel Walczuk
Military Clinical Hospital in Lublin, al. Racławickie 23, 20-049 Lublin, Poland
5 shared publications - Karolina Garbacz
Military Clinical Hospital in Lublin, al. Racławickie 23, 20-049 Lublin, Poland
5 shared publications
Latest Publications
- Open Access
- 17 November 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 33, 55164
Interrelationships between affective disorders in the form of depression and obesity and overweight - A systematic review
Both depression and obesity are significant health, social and economic problems. Depressive disorders were the second most common psychiatric disorder in 2017 after anxiety disorders. According to data published by the World Health Organization (WHO), depression affects about 280 million people worldwide, which is about 3.8 percent of the population. The etiology of depressive disorders is very complex and still not fully understood. The theories described so far complement each other. The factors underlying the development of depressive disorders can be divided into biological, psychological and other factors. Eating disorders in the form of overweight and obesity result from a loss of balance between anabolic and catabolic processes. This is most often led by insufficient physical activity and excess caloric intake. Hormonal disorders, genetic factors and environmental factors may also play an important role in the pathogenesis of obesity. The steadily increasing number of people suffering from depression and obesity prompts the search for links between these two seemingly unrelated disease entities. According to current knowledge, these diseases are bi-directionally linked by genetic, psychological, metabolic and social factors. Depression is associated with an increase in the risk of obesity by about 37% relative to those without depression. Obesity is associated with an increase in the risk of depressive disorders by about 18%. Understanding the links that exist between depressive disorders and obesity enables the search for new therapeutic options. The most important conclusion from the scientific research conducted so far is the advantage of simultaneous treatment of obesity and depression over treating these disease entities individually.
- 17 November 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 33, 55164
Open AccessInterrelationships between affective disorders in the form of depression and obesity and overweight - A systematic review
Both depression and obesity are significant health, social and economic problems. Depressive disorders were the second most common psychiatric disorder in 2017 after anxiety disorders. According to data published by the World Health Organization (WHO), depression affects about 280 million people worldwide, which is about 3.8 percent of the population. The etiology of depressive disorders is very complex and still not fully understood. The theories described so far complement each other. The factors underlying the development of depressive disorders can be divided into biological, psychological and other factors. Eating disorders in the form of overweight and obesity result from a loss of balance between anabolic and catabolic processes. This is most often led by insufficient physical activity and excess caloric intake. Hormonal disorders, genetic factors and environmental factors may also play an important role in the pathogenesis of obesity. The steadily increasing number of people suffering from depression and obesity prompts the search for links between these two seemingly unrelated disease entities. According to current knowledge, these diseases are bi-directionally linked by genetic, psychological, metabolic and social factors. Depression is associated with an increase in the risk of obesity by about 37% relative to those without depression. Obesity is associated with an increase in the risk of depressive disorders by about 18%. Understanding the links that exist between depressive disorders and obesity enables the search for new therapeutic options. The most important conclusion from the scientific research conducted so far is the advantage of simultaneous treatment of obesity and depression over treating these disease entities individually.
- Open Access
- 17 November 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 31, 55297
role of lipoprotein a in cardiac risk stratification and evaluation of hypolipemizing treatment
Introduction and purpose Cardiovascular diseases are one of the most common causes of death. Due to their popularity and the costs they generate, they are a significant problem. One of the cardiovascular risk factors is the level of lipoprotein(a). Lipoprotein (a) levels are not commonly used to stratify cardiovascular risk, but recommendations suggest that every adult should have them checked. The aim of this study is to discuss current knowledge about the role of lipoprotein (a) in cardiac risk stratification and evaluation of hypolipemizing treatment. Material and methods The PubMed database was used to review the literature. An electronic literature search was conducted, publication years were limited to 2018-2024. Three articles that did not meet this criterion due to their earlier publication dates were included because they served as important sources of information for this article. Keywords were used as search terms. Conclusion Based on the available data, the benefits of lowering lipoprotein(a) levels in the context of cardiovascular diseases cannot be confirmed. There is a need for further research into the role of lipoprotein (a) in stratifying cardiovascular risk, the benefits of lowering its levels, and specific therapeutic approaches for this disorder.
- 17 November 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 31, 55297
Open Accessrole of lipoprotein a in cardiac risk stratification and evaluation of hypolipemizing treatment
Introduction and purpose Cardiovascular diseases are one of the most common causes of death. Due to their popularity and the costs they generate, they are a significant problem. One of the cardiovascular risk factors is the level of lipoprotein(a). Lipoprotein (a) levels are not commonly used to stratify cardiovascular risk, but recommendations suggest that every adult should have them checked. The aim of this study is to discuss current knowledge about the role of lipoprotein (a) in cardiac risk stratification and evaluation of hypolipemizing treatment. Material and methods The PubMed database was used to review the literature. An electronic literature search was conducted, publication years were limited to 2018-2024. Three articles that did not meet this criterion due to their earlier publication dates were included because they served as important sources of information for this article. Keywords were used as search terms. Conclusion Based on the available data, the benefits of lowering lipoprotein(a) levels in the context of cardiovascular diseases cannot be confirmed. There is a need for further research into the role of lipoprotein (a) in stratifying cardiovascular risk, the benefits of lowering its levels, and specific therapeutic approaches for this disorder.
- Open Access
- 22 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54723
role of butyric acid in the human body - review
Wprowadzenie i cel: Kwas masłowy jest jednym z najważniejszych krótkołańcuchowych kwasów tłuszczowych (SCFA) wytwarzanych w ludzkim jelicie grubym. Celem tego artykułu jest podkreślenie jego funkcji i potencjalnych zastosowań w praktyce klinicznej. Analizując wyniki badań i publikacje naukowe, podejmiemy próbę wyjaśnienia znaczenia kwasu masłowego w funkcjonowaniu ludzkiego ciała. Cel pracy: Celem niniejszej pracy było przedstawienie wyników badań naukowych dotyczących funkcji i zastosowania kwasu masłowego w medycynie. Materiały i metody: Niniejszy przegląd opiera się na analizie materiałów pochodzących z bazy PubMed i różnych artykułów naukowych, wykorzystujących takie słowa kluczowe, jak „kwas masłowy”, „maślan”, „nieswoiste zapalenie jelit”, „odporność”, „mikrobiota jelitowa” i „krótkołańcuchowe kwasy tłuszczowe”. Opis stanu wiedzy: Mikrobiota jelitowa jest przedmiotem badań naukowych od wielu lat, jednak znaczenie jej produktów metabolicznych, w tym kwasu masłowego, jest dopiero teraz w pełni zrozumiane. Obecny stan wiedzy daje nadzieję na stosowanie kwasu masłowego w takich schorzeniach jak choroby zapalne jelit, co potwierdzają liczne badania. Przeciwzapalne właściwości tego metabolitu bakterii jelitowych sugerują również potencjalne korzyści w chorobach neurodegeneracyjnych i sercowo-naczyniowych, co podkreślają cytowane tutaj prace naukowe, które potwierdzają takie zastosowania . Wnioski : Kwas masłowy, jako produkt metaboliczny mikrobiomu jelitowego, ma potencjał, aby stać się znaczącym suplementem w różnych dziedzinach medycyny. Niniejszy przegląd, który bada jego działania i zastosowania, dostarcza wglądu w jego możliwe funkcje i daje nadzieję na przyszłe opcje terapeutyczne.
- 22 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54723
Open Accessrole of butyric acid in the human body - review
Wprowadzenie i cel: Kwas masłowy jest jednym z najważniejszych krótkołańcuchowych kwasów tłuszczowych (SCFA) wytwarzanych w ludzkim jelicie grubym. Celem tego artykułu jest podkreślenie jego funkcji i potencjalnych zastosowań w praktyce klinicznej. Analizując wyniki badań i publikacje naukowe, podejmiemy próbę wyjaśnienia znaczenia kwasu masłowego w funkcjonowaniu ludzkiego ciała. Cel pracy: Celem niniejszej pracy było przedstawienie wyników badań naukowych dotyczących funkcji i zastosowania kwasu masłowego w medycynie. Materiały i metody: Niniejszy przegląd opiera się na analizie materiałów pochodzących z bazy PubMed i różnych artykułów naukowych, wykorzystujących takie słowa kluczowe, jak „kwas masłowy”, „maślan”, „nieswoiste zapalenie jelit”, „odporność”, „mikrobiota jelitowa” i „krótkołańcuchowe kwasy tłuszczowe”. Opis stanu wiedzy: Mikrobiota jelitowa jest przedmiotem badań naukowych od wielu lat, jednak znaczenie jej produktów metabolicznych, w tym kwasu masłowego, jest dopiero teraz w pełni zrozumiane. Obecny stan wiedzy daje nadzieję na stosowanie kwasu masłowego w takich schorzeniach jak choroby zapalne jelit, co potwierdzają liczne badania. Przeciwzapalne właściwości tego metabolitu bakterii jelitowych sugerują również potencjalne korzyści w chorobach neurodegeneracyjnych i sercowo-naczyniowych, co podkreślają cytowane tutaj prace naukowe, które potwierdzają takie zastosowania . Wnioski : Kwas masłowy, jako produkt metaboliczny mikrobiomu jelitowego, ma potencjał, aby stać się znaczącym suplementem w różnych dziedzinach medycyny. Niniejszy przegląd, który bada jego działania i zastosowania, dostarcza wglądu w jego możliwe funkcje i daje nadzieję na przyszłe opcje terapeutyczne.
- Open Access
- 22 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 70, 49802
Does sauna bathing prevent chronic obstructive pulmonary disease or Alzheimer's disease? May adults with cardiovascular disease use a sauna? A systematic review
Recently, there has been a surge of interest in sauna bathing and its role in health aspects. However, there are few studies focusing on the association between regular sauntering and the risk of dementia and chronic obstructive pulmonary disease (COPD). Considerably better understood are the effects on the cardiovascular system. This study delves into contemporary scientific research on Finnish saunas, exploring their potential correlation with Alzheimer's disease prevention, their impact on vascular health in adults with cardiovascular disorders, and their association with reducing the risk of chronic obstructive pulmonary disease. Scientific studies published in PubMed, Scopus and Google Scholar databases were analyzed, including terms related to Finnish sauna, dementia, COPD and cardiovascular disease. The methodological quality and results of each study were evaluated. Sauna bathing in addition to being a relaxing lifestyle habit, remains a potential additional strategy which can be used in improving cardiovascular function in adults with well-controlled cardiovascular disorders. A limited amount of research has been identified on the correlation between sauna bathing and reduced risk of Alzheimer's disease and COPD. The accumulating evidence suggests that frequent sauna bathing may reduce the risk or severity of several vascular and nonvascular conditions including COPD and also moderate to high frequency of sauna bathing was associated with lowered risks of dementia and Alzheimer’s disease. Further research is required, especially large-scale cohort studies with repeated measurement on sauna to establish the potential mechanisms linking sauna bathing and either memory diseases or COPD and better understand the relationship between sauntering and cardiovascular health. Upcoming studies may become very promising for the development of sauna bathing as a new non-pharmacological treatment or prevention of various diseases and improvement in the quality of life.
- 22 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 70, 49802
Open AccessDoes sauna bathing prevent chronic obstructive pulmonary disease or Alzheimer's disease? May adults with cardiovascular disease use a sauna? A systematic review
Recently, there has been a surge of interest in sauna bathing and its role in health aspects. However, there are few studies focusing on the association between regular sauntering and the risk of dementia and chronic obstructive pulmonary disease (COPD). Considerably better understood are the effects on the cardiovascular system. This study delves into contemporary scientific research on Finnish saunas, exploring their potential correlation with Alzheimer's disease prevention, their impact on vascular health in adults with cardiovascular disorders, and their association with reducing the risk of chronic obstructive pulmonary disease. Scientific studies published in PubMed, Scopus and Google Scholar databases were analyzed, including terms related to Finnish sauna, dementia, COPD and cardiovascular disease. The methodological quality and results of each study were evaluated. Sauna bathing in addition to being a relaxing lifestyle habit, remains a potential additional strategy which can be used in improving cardiovascular function in adults with well-controlled cardiovascular disorders. A limited amount of research has been identified on the correlation between sauna bathing and reduced risk of Alzheimer's disease and COPD. The accumulating evidence suggests that frequent sauna bathing may reduce the risk or severity of several vascular and nonvascular conditions including COPD and also moderate to high frequency of sauna bathing was associated with lowered risks of dementia and Alzheimer’s disease. Further research is required, especially large-scale cohort studies with repeated measurement on sauna to establish the potential mechanisms linking sauna bathing and either memory diseases or COPD and better understand the relationship between sauntering and cardiovascular health. Upcoming studies may become very promising for the development of sauna bathing as a new non-pharmacological treatment or prevention of various diseases and improvement in the quality of life.
- Open Access
- 21 February 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 62, 61-75
Lichen planus: A Systematic Review
Lichen planus (LP) is a chronic skin, mucous membrane, and nail disease. Lichen planus is a rare skin condition occurring in less than 1% of the general population, affecting both children and adults. Oral lichen planus (OLP) involvement is much more common. It is an autoimmune disease caused by T lymphocytes, with epigenetic factors playing a significant role in the development of autoimmune skin diseases. MicroRNAs (miRNAs), a group of non-coding RNAs, play a substantial role in regulating the immune response.1 The etiology of lichen planus in not fully understood. It can be triggered by antihypertensive drugs, beta-blockers, infections, viral hepatitis, psychological stress, and others. Cases of lichen planus appearing after recovering from COVID-19 have been reported, as well as a significant increase in cases after COVID-19 vaccination.2–5 Diagnosis is based on clinical presenstation and characteristic histopathological findings. The disease is often self-limiting, accompanied by persistent itching and painful erosions of the mucous membrane, affecting the patient’s quality of life and mental well-being. First-line treatments inculde topical corticosteroids and/or oral corticosteroids. There are reports of new potential treatments, such as biologic drugs (anti-IL12/13, anti-IL17) and Janus kinase inhibitors. Consequently, a dramatic change in lichen planus treatment can be expected in the near future. The majority of patients suffering from lichen planus develop metabolic syndrome which is the cause of other diseases. This article provides a comprehensive overview of current knowledge about lichen planus and its variants.
- 21 February 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 62, 61-75
Open AccessLichen planus: A Systematic Review
Lichen planus (LP) is a chronic skin, mucous membrane, and nail disease. Lichen planus is a rare skin condition occurring in less than 1% of the general population, affecting both children and adults. Oral lichen planus (OLP) involvement is much more common. It is an autoimmune disease caused by T lymphocytes, with epigenetic factors playing a significant role in the development of autoimmune skin diseases. MicroRNAs (miRNAs), a group of non-coding RNAs, play a substantial role in regulating the immune response.1 The etiology of lichen planus in not fully understood. It can be triggered by antihypertensive drugs, beta-blockers, infections, viral hepatitis, psychological stress, and others. Cases of lichen planus appearing after recovering from COVID-19 have been reported, as well as a significant increase in cases after COVID-19 vaccination.2–5 Diagnosis is based on clinical presenstation and characteristic histopathological findings. The disease is often self-limiting, accompanied by persistent itching and painful erosions of the mucous membrane, affecting the patient’s quality of life and mental well-being. First-line treatments inculde topical corticosteroids and/or oral corticosteroids. There are reports of new potential treatments, such as biologic drugs (anti-IL12/13, anti-IL17) and Janus kinase inhibitors. Consequently, a dramatic change in lichen planus treatment can be expected in the near future. The majority of patients suffering from lichen planus develop metabolic syndrome which is the cause of other diseases. This article provides a comprehensive overview of current knowledge about lichen planus and its variants.